Dymaxium welcomes Lauren Cuddy and Michael Drummond to its team

TORONTO, Oct. 3, 2013 /CNW/ - Dymaxium is pleased to welcome Lauren Cuddy and Michael Drummond both as investors and as members of its Board of Directors. Cuddy and Drummond bring their entrepreneurial spirit, extensive health economics and outcomes research (HEOR) experience, health care and formulary decision maker (payer) expertise, and business acumen to the Dymaxium team.

The addition of Cuddy and Drummond to the executive team will further support Dymaxium as it executes on its strategic vision: assisting the interaction between payers and pharmaceutical and biotechnology manufacturers through innovative platforms that support making informed evidence-based product evaluations and formulary decisions to improve patient outcomes.

Lauren Cuddy was an executive vice president with OptumInsight (part of UnitedHealth Group) for the past six years. Previously, she was the president/CEO of Innovus Research and led its growth from its beginning as a small Canadian company to becoming the leader in global HEOR consulting before it was acquired by i3 Ingenix/UnitedHealth Group.

Michael Drummond is one of the world's preeminent thought leaders and academic consultants in health technology assessment (HTA), HEOR, and evidence-based decision making. He is a professor at the University of York in the U.K. and has been a consultant to the World Health Organization and leading HTA/payer and pharmaceutical industry organizations. 

Cuddy said, "I am excited to join the team at Dymaxium, as I have always felt Dymaxium has been one of the most innovative and forward-thinking companies in this industry. I look forward to working with Allen Lising and Paul Pijuan to help the company grow and increase its global brand. I see the same energy and spirit in Dymaxium that we had many years ago when I led Innovus."

Drummond said, "Evidence-based product evaluations, health technology assessments, and formulary decision making have been my main interests over the years. This is something I am passionate about. I believe that Dymaxium's platforms, especially the FormularyDecisions platform [the AMCP eDossier System in the U.S.] will further drive innovation in this field, and I am glad to be part of these developments."

Since 1996, Dymaxium has been an industry leader in providing interactive solutions to optimize how scientific evidence is presented to payers. Today, its FormularyDecisions.com® platform is the premier platform for U.S. formulary decision makers in payer organizations to request, review, and evaluate the latest information on new and existing products.

"Dymaxium has focused on the advancement of 'interfacing with payers' from traditional HEOR tools to its payer platforms," stated Allen Lising, managing director and one of the company's co-founders, along with Paul Pijuan. "We are launching version 2.0 of our payer platform in November, which will be evolutionary in formulary decision-making processes and revolutionary in product evaluations. With Lauren and Mike, we will strive to continue the innovation and look to grow both in the U.S. and globally."

Biographical Information

Lauren Cuddy, MA, MBA, is a senior business leader whose career has ranged from entrepreneurial startups through to multinational public companies. Cuddy was a founder of Innovus Research in 1984 and led the company to a position of global dominance in health economics and outcomes research before selling the company to OptumInsight, a division of UnitedHealth Group, in 1996. She held the position of executive vice president in the Life Sciences division of OptumInsight until 2012. Lauren has served on a number of boards, including those of McMaster University, the McMaster Alumni Association, Joseph Brant Memorial Hospital, the Innovators Alliance, the Golden Horseshoe Biosciences Network, and the Innovation Factory. She received her MA and MBA from McMaster University, and was inducted into the McMaster Alumni Gallery in 2005.

Michael Drummond, BSc, MCom, DPhil, is a professor of health economics and the former director of the Centre for Health Economics at the University of York in the U.K. His particular field of interest is in the economic evaluation of health care treatments and programs. He has undertaken evaluations in a wide range of medical fields, including eldercare, neonatal intensive care, immunization programs, services for people with AIDS, eye health, and pharmaceuticals. He is the author of two major textbooks and more than 600 scientific papers, has acted as a consultant to the World Health Organization, and was the project leader of a European Union project on the Methodology of the Economic Appraisal of Health Technology. He has been the president of the International Society of Technology Assessment in Health Care, and of the International Society for Pharmacoeconomics and Outcomes Research. He was a member of the Guidelines Review Panels of the National Institute for Health and Clinical Excellence (NICE) in the U.K. from 2000 to 2011, and is a principal consultant for OptumInsight. In October 2010, he was made a member of the U.S. Institute of Medicine. He is currently co-editor-in-chief of Value in Health.

About Dymaxium

Dymaxium is focused on interfacing with payers, providing both a FormularyDecisions.com platform for an exclusive community of health care decision makers in payer organizations and interface tools and solutions for pharma teams to engage and communicate with payer customers.

Founded in 1996, Dymaxium provides interactive, user-friendly, graphical tools and solutions to communicate scientific evidence and product value. It has successfully delivered more than 700 solutions to pharmaceutical, biotech, and medical device manufacturers in the U.S., U.K., Europe, Canada, and Asia.

In 2007, it evolved its vision to directly support payers with its Outcomes Analyzer platform. The FormularyDecisions.com® platform was launched in the U.S. in 2010 as the AMCP eDossier System, in partnership with the Academy of Managed Care Pharmacy (AMCP). Since then, it has become the premier evidence-based product evaluation platform in the U.S.

SOURCE: Dymaxium Inc.

For further information:

Please contact Sharon Sears.
Telephone: (416) 348-9339 Ext. 233
Email:  ssears@dymaxium.com
Website: www.dymaxium.com

Profil de l'entreprise

Dymaxium Inc.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.